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Abstract
Pulmonary involvement in Crohn’s disease (CD) may precede the development
of intestinal inflammation, but in most cases occurs during the course of treat-
ment, either as an extra-intestinal manifestation, because of secondary infections,
or as a side effect of the therapy itself. This case highlights the differential diag-
nosis and work up for multiple pulmonary nodules that developed in a patient
with CD who had been in remission on infliximab therapy. Even though infec-
tious causes, such as Mycobacteria and Fungi, account for majority of these cases,
the possibility of non-infectious conditions such as autoimmune disorders
should also be considered.
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Abbreviations:
ANA anti-nuclear antibody
ANCA anti-neutrophil cytoplasmic antibody
BAL bronchoalveolar lavage
CD Crohn’s disease
CT computed tomography
GPA granulomatosis with polyangiitis
IL interleukin
IV intravenous
LGPA limited form of granulomatosis with polyangiitis
PCR polymerase chain reaction
TB tuberculosis
TNF tumor necrosis factor
Introduction
Crohn’s disease (CD) is characterised by chronic
inflammation in the gastrointestinal tract, typically
involving the terminal ileum and/or perianal region, in
a transmural, non-contiguous fashion (1). Treatment
decisions are based on localisation/extent of disease
activity, and associated complications (2). Chimeric
anti-tumor necrosis factor-alpha (TNF-α) antibodies
such as infliximab, adalimumab and certolizumab have
The Clinical Respiratory Journal CASE REPORT
1The Clinical Respiratory Journal (2014) • ISSN 1752-6981
© 2014 John Wiley & Sons Ltd
l i i : , a a i S, Debelenko LV, c rat J, utyala
, l i . i it gr l i it l ii i i a adolesce t ith
’s i s i fli i : i i li es i J 2015; 9:
506–511. DOI: 0. 111/crj.12168.
The Clinical Respiratory Journal (2015) • ISSN 1752-698
VC 2014 John Wiley & Sons Ltd
506
l
been used to induce remission, either alone or in com-
bination with other agents (3).
Pulmonary involvement in CD can sometimes
precede the development of intestinal inflammation
(4), or occur during the course of treatment – either as
an extra-intestinal manifestation of CD (5), because of
secondary infections or as a side effect of the therapy
itself (6). Granulomatous inflammation within the
airways or lung parenchyma can occur due to CD but
can also occur because of several other forms of
primary and secondary lung disorders (Table 1). We
present an unusual case of a 19-year old patient with
stable CD who developed multiple pulmonary nodules
while on therapy with infliximab. The approach to
initial diagnostic work up, differential diagnosis of
granulomatous lung disorders and their salient differ-
entiating features on lung histology, as well as manage-
ment is discussed.
Case report
A 19-year old Caucasian female with history of CD was
admitted with sudden onset of severe, sharp chest pain,
localised to the left upper sternal border, radiating to
the left neck and shoulder; worsening with deep inspi-
ration. There was no history of trauma to the chest,
shortness of breath, palpitations, sweating, fever, cough
or hemoptysis. CD with perianal fistulae was diag-
nosed 5 years ago and well controlled with intravenous
infliximab infusion given every 7 weeks. On examina-
tion, she had stable vital signs with shallow breaths but
normal oxygen saturation on room air. Eczematous
dry skin was noted on her feet. The rest of the exami-
nation was benign. Initial laboratory results revealed
white blood cell count of 11 000/mm3 with normal
differential, hemoglobin 13.3 gm/dL, hematocrit of
39.1%, platelets 355 000/mm3; C-reactive protein,
132 mg/L, erythrocyte sedimentation rate, 49 mm,
D-dimer 0.5 mg/L (normal < 0.59). Initial chest radio-
graph was normal (Fig. 1A). Because of oral contra-
ceptive use (ethinyl estradiol/norgestimate), a chest
computed tomography (CT) scan done to rule out
pulmonary embolism revealed the presence of multi-
ple pulmonary nodules, with the largest one in left
lower lobe measuring 1.3 cm (Fig. 1B).
Given the patient’s infliximab use, an infectious aeti-
ology was initially suspected and further treatment
with infliximab withheld. Blood for bacterial culture,
fungal serology and fungal antigens (beta-d-glucan,
cryptococcal and blastomyces antigen) were negative.
A flexible fibre-optic bronchoscopy showed normal
airway anatomy and mucosal surfaces. Bacterial,
mycobacterial and fungal stains and culture; myco-
plasma and viral cultures; pneumocystis stain and
polymerase chain reaction (PCR) for viral DNA from
bronchoalveolar lavage (BAL) fluid were all negative.
Negative purified protein derivative skin test and
serum interferon gamma release assay ruled out
mycobacterial infections.
In the next few days there was worsening of chest pain
with tachypnea and a repeat chest CT showed increase
in the number and size of the pulmonary nodules
(Fig. 1C), and CT abdomen was negative for mass
lesions. Intravenous amphotericin B and ceftriaxone
were started empirically. Further investigations
revealed serum anti-nuclear antibody titre of 1:640,
negative anti-dsDNA, c-anti-neutrophil cytoplasmic
antibody (c-ANCA), p-ANCA and anti-infliximab
antibodies; and normal levels of complement (C3 and
C4), angiotensin-converting enzyme, serum calcium
and Vitamin D. A negative nitro blue tetrazolium test
ruled out chronic granulomatous disease, and bone
marrow biopsy was negative for hematopoietic malig-
nancy. Finally, an open lung biopsy was obtained for
evaluation of lung pathology and microbiology. The
special stains of lung tissue were negative for fungus
Table 1. Differential diagnosis of granulomatous disorders of
the lungs
Infectious Non-infectious
Mycobacteria
Mycobacterium
tuberculosis
Non-tuberculous
mycobacteria
Rheumatologic
Sarcoidosis
Granulomatosis with polyangiitis
(formerly Wegener’s
Granulomatosis)
Rheumatoid nodules
Churg Strauss Syndrome
Fungi Hypersensitivity
Histoplasma Hypersensitivity pneumonitis
Coccidioides Talc Granulomatosis
Blastomyces Berylliosis
Paracoccidioides
Cryptococcus
Aspergillus
Pneumocystis
Parasitic infestations Immune
Cestodes Chronic granulomatous disease
Granulomatous Lymphocytic
Interstitial Lung Disease
(associated with Common
Variable Immune Deficiency)
Lymphocytic Interstitial Pneumonitis
in HIV infected individuals
Echinococcus
Nematodes
Toxocara
Dirofilaria
Trematodes
Schistosoma
Paragonimus
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and mycobacteria, including pan-bacterial, -fungal and
-mycobacterial PCR testing.
Histopathology of lung nodules revealed massive
geographic necrosis and necrotising granulomas that
were surrounded by palisading histiocytes (Fig. 2A).
Pulmonary vasculitis with adventitial fibrosis, focal
intimal hyperplasia and sub-endothelial fibro-
histiocystic proliferation with presence of fibrin
thrombi in smaller vessels were also noted (Fig. 2B).
Inflammatory changes were seen in bronchioles, pleura
and alveoli. The observed picture of geographic necro-
sis and palisading granulomas with neutrophilic/
karyorrhectic centres as well as vasculitis, in the
absence of infection, was consistent with limited form
of granulomatosis with polyangiitis (LGPA) (Table 2).
The diagnosis of LGPA was confirmed by an additional
independent review by three pulmonary pathologists
from another academic institution. Lower gastrointes-
tinal biopsies performed a month later to assess CD
activity revealed minimally active CD with rare small
non-necrotising epitheloid granulomas (Fig. 2C) and
focal cryptitis (Fig. 2D).
Treatment with high-dose intravenous steroids for
3 days followed by a tapered regimen was instituted.
The patient showed rapid clinical improvement in her
symptoms within hours of initiation of the steroid
therapy. She was also started on methotrexate 20 mg
subcutaneous once a week (as additional steroid-
sparing therapy). Follow-up chest CT scan done
3 months later (Fig. 1D) showed complete resolution
of the nodules.
Discussion
The differential diagnosis of granulomatous lung dis-
orders includes various infectious and non-infectious
causes (Table 1) (7). Further delineation could be done
based on specific features of the granulomas and other
cellular components (Table 2). This case highlights the
important differential diagnoses for pulmonary lesions
in a patient with CD who had been in remission on
infliximab therapy. The initial concern was for an
infectious aetiology which is generally the most
common cause (8), but it was ruled out in our case
after negative special stains and cultures of BAL and
lung tissue for fungal and mycobacterial organisms;
and negative advanced PCR testing results. The lung
biopsy showed necrotising granulomatous inflamma-
tion with angiocentric granulomas and vasculitis, and
this narrowed our differential diagnosis to pulmonary
involvement in CD, granulomatosis with polyangiitis
(GPA) and sarcoidosis (Table 2). However, our patient
had been asymptomatic from the standpoint of gastro-
intestinal symptoms, had a normal magnetic reso-
nance enterography study, with minimal activity on
lower gastrointestinal biopsy. Geographic necrosis and
vasculitis are generally lacking within the granulomas
seen with pulmonary involvement in CD (9), whereas
Figure 1. Radiologic Images for index
case. (A) Chest radiograph (antero-
posterior view) at the time of initial
presentation. (B) Chest computed
tomography (CT) scan at initial presen-
tation showing multiple small subpleural
nodules. (C) Chest CT scan 1 week later
showing increased size and number of
lung nodules. (D) Chest CT scan
3 months after initiation of treatment
showing near complete resolution of
nodules.
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Figure 2. Pulmonary and intestinal pathology. (A) Pulmonary biopsy demonstrating a palisading granuloma with necrotic centre
filled with neutrophils and karyorrhectic debris and surrounded by histiocytes. Hematoxylin-eosin, original magnification ×200. (B)
Pulmonary biopsy demonstrating a small artery involved by vasculitis with fibrin deposits (arrow). Hematoxylin-eosin, original
magnification ×400. (C) Colonic biopsy demonstrating a small compact non-necrotising granuloma composed of epitheloid
histiocytes, characteristic of Crohn’s disease. Hematoxylin-eosin, original magnification ×600. Note the difference between the
appearance of colonic (C) and pulmonary (A) granulomas. (D) Colonic biopsy demonstrating chronic, mildly active colitis with a
single crypt involved by cryptitis in the centre. Hematoxylin-eosin, original magnification ×400.
Table 2. Distinguishing features of non-infectious granulomatous inflammation of the lungs (pulmonary Crohn’s disease,
granulomatosis with polyangiitis and sarcoidosis) (10)
Features
Primary Crohn’s disease
involving the lung Granulomatosis with polyangiitis Sarcoidosis
Distribution Bronchocentric Angiocentric, pleural based Diffuse bronchovascular with hilar
adenopathy
Granulomas Small Non-necrotic,
non-caseating granulomas
with epitheloid histiocytes
Necrotising granulomas of various
sizes, frequently large, geographic,
with neutrophilic/karyorrhectic
centres and palisading histiocytes
with occasional multinucleated giant
cells at the periphery
Uniform small-to-medium sized
granulomas, characteristically
non-necrotising composed of
epitheloid histiocytes and frequent
multinucleated giant cells
Presence of
necrosis
Generally non-necrotising Central necrosis may be confluent or
show irregular serpiginous pattern
known as ‘geographic necrosis’
Generally non-necrotising; small areas
of central necrosis can be
occasionally seen.
Vascular
changes
None Necrotising vasculitis affecting small to
medium sized vessels
None
Inclusions None None Asteroid Bodies
Schaumann bodies
Hamazaki–Wesenberg bodies
Calcium oxalate
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the granulomas seen in sarcoidosis are typically well
formed, non-necrotising, with numerous epitheloid
cells and giant cells. As seen in our case, the granulo-
mas seen in GPA are generally poorly formed, show
palisading histiocytes, and are accompanied by vascu-
litis and a mixed inflammatory infiltrate (10).
Pulmonary involvement in CD is variable and may
result from disease itself or associated medical therapy.
Casey et al. reported chronic bronchitis and bron-
chiolitis with non-necrotising granulomatous inflam-
mation as the most common forms (9/25; 36%) of
pulmonary involvement (11). Many of the agents used
for therapy of inflammatory bowel diseases (including
mesalamine) are known to cause pulmonary side
effects (12). Tayer-Shifman et al. reported a case of CD
with multiple pulmonary cavitary nodules and
c-ANCA positivity that was attributed to mesalamine
(13), but their patient had complete resolution of pul-
monary nodules after its discontinuation (even though
c-ANCA positivity continued). Our patient had not
been treated with mesalamine and had negative
c-ANCA. This brings up the question of whether
there is a link between the pathways of inflammation
that are involved in CD and GPA and whether immune
modulators (such as mesalamine or infliximab) could
induce other alternative immune mechanisms/path-
ways that increases the risk for the development of
autoimmune disease and/or vasculitis in these patients.
There is some indication that the interleukin-17 (IL-
17) pathway could be the common link in these two
conditions (14).
Infliximab has been used for therapy of CD for more
than a decade now, and a review of 233 cases treated
with anti-TNF alpha therapies showed that cutaneous
vasculitis was the most common manifestation, and
lung involvement primarily occurred in the form of
interstitial lung disease (15). There have been several
reports of infectious (16–18) and non-infectious (6,
19–21) pulmonary complications in patients with CD
while on infliximab therapy. Hypersensitivity vasculitis
with leukocytoclastic vasculitis (22, 23) due to use of
infliximab was unlikely because of lack of cutaneous
involvement in our patient.
There is a possibility of secondary autoimmune
disease developing in patients on long-term anti-TNF
therapy, and a recent review by Ramos-Casals (15)
reported that one quarter of these patients had extra-
cutaneous vasculitis. To our knowledge, there are only
two other case reports that have reported the occur-
rence of GPA in patients with CD, but none of those
patients had been on infliximab therapy (24, 25). Our
patient’s presentation fits with the description of
‘limited’ form of GPA, which is known to be localised
to the lungs, is more common in females, has a younger
age of onset, and is less likely to be associated with
ANCA positivity (26). ANCA negative GPA is generally
associated with lower incidence of renal involvement
and better long-term survival (27). ANCA positivity is
not an absolute requirement for the diagnosis of GPA
as per the American College of Rheumatology criteria
(28) or in the updated definition provided by the
Chapel Hill Consensus Conference (29).
To conclude, our case highlights the fact that second-
ary autoimmune disease can develop in patients with
CD on infliximab therapy and that nodular pulmonary
lesions having features of granulomatous inflammation
have a broad differential diagnosis. We have also high-
lighted the importance of lung histopathology in estab-
lishing the diagnosis. Even though infectious causes
account for majority of these cases, the possibility of
non-infectious conditions such as autoimmune disor-
ders should be considered after carefully excluding
infectious organisms such as mycobacteria and fungi.
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